Plain-English translation of NCT06605794 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new device called the FreeFlow percutaneous atrial septal shunt, which is implanted in the heart to help people with a serious condition called idiopathic pulmonary arterial hypertension. In this condition, blood pressure in the arteries that supply the lungs becomes dangerously high, making it hard to breathe and putting strain on the heart. The trial wants to find out if this device is safe and whether it can reduce deaths and hospital readmissions.
Idiopathic pulmonary arterial hypertension is a life-threatening disease with limited treatment options, and patients often continue to struggle even with the best available medications. This trial exists to see whether this new implantable device could offer hope to patients who need additional help managing their condition.
You likely qualify if…
You likely don't qualify if…
If accepted, you will undergo a heart catheterization procedure where doctors will create a small opening between the chambers of your heart and implant the FreeFlow device. You will then be followed closely with visits at 24 hours after the procedure, then at 1 month, 3 months, 6 months, and 12 months. At each visit, your doctors will check how well the device is working and how you are feeling through physical exams and tests.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
China